Journal of Neurology

, Volume 262, Issue 11, pp 2572–2577 | Cite as

Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis

  • Rick Dersch
  • Antonia A. Sarnes
  • Monika Maul
  • Tilman Hottenrott
  • Annette Baumgartner
  • Sebastian Rauer
  • Oliver Stich
Original Communication
First Online:
Received:
Revised:
Accepted:

Abstract

The prognosis and impact of residual symptoms on quality of life in patients with Lyme neuroborreliosis (LNB) is subject to debate. The aim of this study was to assess quality of life, fatigue, depression, cognitive impairment and verbal learning in patients with definite LNB and healthy controls in a case–control study. We retrospectively identified all patients diagnosed with definite LNB between 2003 and 2014 in our tertiary care center. Healthy controls were recruited from the same area. Patients and healthy controls were assessed for quality of life [Short Form (36) with subscores for physical and mental components (PCS, MCS)], fatigue (fatigue severity scale), depression (Beck depression inventory), verbal memory and learning and cognitive impairment (mini-mental state examination). 53 patients with definite LNB could be identified, of which 30 partook in the follow-up assessment. Estimates for quality of life, fatigue, depression, verbal memory and cognitive impairment did not differ statistically significantly between 30 patients with LNB and 35 healthy controls. Patients with residual symptoms had lower scores for quality of life (PCS) compared to patients without residual symptoms. Our results do not support the hypothesis that a considerable proportion of patients with antibiotically treated LNB develop a ‘post Lyme syndrome’ consisting of debilitating fatigue or cognitive impairment or have severe limitations of quality of life. However, some patients experience residual symptoms of LNB.

Keywords

Lyme neuroborreliosis Fatigue Quality of life Depression Verbal memory Cognitive impairment Follow-up Case–control study 
This is a preview of subscription content, log in to check access.

Notes

Compliance with ethical standards

Conflicts of interest

RD, AS, MM, TH and AB have nothing to declare. SR reports receiving consulting and lecture fees, grant and research support from Bayer Vital GmbH, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, Baxter, RG, and Teva. Furthermore, SR indicates that he is a founding executive board member of ravo Diagnostika GmbH. All other authors declare that they have no competing interests. OS reports receiving consulting and lecture fees, grant and research support from Baxter, Bayer Vital GmbH, Biogen Idec, Genzyme, Merck Serono, Novartis, RG, Sanofi-Aventis and Teva.

Ethical standard

The study was approved by the ethics committee of the Medical Center, University of Freiburg. Informed consent was obtained from every participant.

References

  1. 1.
    Huppertz HI, Bohme M, Standaert SM, Karch H, Plotkin SA (1999) Incidence of Lyme borreliosis in the Wurzburg region of Germany. Eur J Clin Microbiol 18(10):697–703CrossRefGoogle Scholar
  2. 2.
    Berglund J, Stjernberg L, Ornstein K, Tykesson-Joelsson K, Walter H (2002) 5-y Follow-up study of patients with neuroborreliosis. Scand J Infect Dis 34(6):421–425CrossRefPubMedGoogle Scholar
  3. 3.
    Kaiser R (1998) Neuroborreliosis. J Neurol 245(5):247–255CrossRefPubMedGoogle Scholar
  4. 4.
    Pfister HW, Einhaupl KM, Wilske B, Preac-Mursic V (1987) Bannwarth’s syndrome and the enlarged neurological spectrum of arthropod-borne borreliosis. Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene Series A 263(3):343–347CrossRefGoogle Scholar
  5. 5.
    Kaiser R (2004) Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone. Nervenarzt 75(6):553–557CrossRefPubMedGoogle Scholar
  6. 6.
    Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I et al (2010) EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 17(1):8–16, e1–4CrossRefPubMedGoogle Scholar
  7. 7.
    Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS et al (2006) The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43(9):1089–1134CrossRefPubMedGoogle Scholar
  8. 8.
    Cameron D, Gaito A, Harris N, Bach G, Bellovin S, Bock K et al (2004) Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti-infect Ther 2(1 Suppl):S1–S13PubMedGoogle Scholar
  9. 9.
    Patel R, Grogg KL, Edwards WD, Wright AJ, Schwenk NM (2000) Death from inappropriate therapy for Lyme disease. Clin Infect Dis 31(4):1107–1109CrossRefPubMedGoogle Scholar
  10. 10.
    Holzbauer SM, Kemperman MM, Lynfield R (2010) Death due to community-associated Clostridium difficile in a woman receiving prolonged antibiotic therapy for suspected lyme disease. Clin Infect Dis 51(3):369–370CrossRefPubMedGoogle Scholar
  11. 11.
    Auwaerter PG, Bakken JS, Dattwyler RJ, Dumler JS, Halperin JJ, McSweegan E et al (2011) Antiscience and ethical concerns associated with advocacy of Lyme disease. Lancet Infect Dis 11(9):713–719PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Cerar D, Cerar T, Ruzic-Sabljic E, Wormser GP, Strle F (2010) Subjective symptoms after treatment of early Lyme disease. Am J Med 123(1):79–86CrossRefPubMedGoogle Scholar
  13. 13.
    Kalish RA, Kaplan RF, Taylor E, Jones-Woodward L, Workman K, Steere AC (2001) Evaluation of study patients with Lyme disease, 10–20-year follow-up. J Infect Dis 183(3):453–460CrossRefPubMedGoogle Scholar
  14. 14.
    Skogman BH, Croner S, Nordwall M, Eknefelt M, Ernerudh J, Forsberg P (2008) Lyme neuroborreliosis in children: a prospective study of clinical features, prognosis, and outcome. Pediatr Infect Dis J 27(12):1089–1094CrossRefPubMedGoogle Scholar
  15. 15.
    Eikeland R, Mygland A, Herlofson K, Ljostad U (2011) European neuroborreliosis: quality of life 30 months after treatment. Acta Neurol Scand 124(5):349–354CrossRefPubMedGoogle Scholar
  16. 16.
    Benke T, Gasse T, Hittmair-Delazer M, Schmutzhard E (1995) Lyme encephalopathy: long-term neuropsychological deficits years after acute neuroborreliosis. Acta Neurol Scand 91(5):353–357CrossRefPubMedGoogle Scholar
  17. 17.
    Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33(5):337–343CrossRefPubMedGoogle Scholar
  18. 18.
    Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–1123CrossRefPubMedGoogle Scholar
  19. 19.
    Helmstaedter C, Lendt M, Lux S (2001) Verbaler Lern- und Merkfähigkeitstest: VLMT. Beltz Test, GöttingenGoogle Scholar
  20. 20.
    Ljostad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A et al (2008) Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol 7(8):690–695CrossRefPubMedGoogle Scholar
  21. 21.
    Schulz KF, Grimes DA (2002) Case–control studies: research in reverse. Lancet 359(9304):431–434CrossRefPubMedGoogle Scholar
  22. 22.
    Eikeland R, Ljostad U, Mygland A, Herlofson K, Lohaugen GC (2012) European neuroborreliosis: neuropsychological findings 30 months post-treatment. Eur J Neurol 19(3):480–487CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Rick Dersch
    • 1
  • Antonia A. Sarnes
    • 1
  • Monika Maul
    • 1
  • Tilman Hottenrott
    • 1
  • Annette Baumgartner
    • 1
  • Sebastian Rauer
    • 1
  • Oliver Stich
    • 1
  1. 1.Department of Neurology, Medical CenterUniversity of FreiburgFreiburgGermany

Personalised recommendations